Abstract
The microdialysis technique was initially developed for monitoring neurotransmitters in animals. In 1995 the technique was adopted to clinical use and bedside enzymatic analysis of glucose, pyruvate, lactate, glutamate and glycerol. Under clinical conditions microdialysis has also been used for studying cytokines, protein biomarkers, multiplex proteomic and metabolomic analyses as well as for pharmacokinetic studies and evaluation of blood-brain barrier function. This review focuses on the variables directly related to cerebral energy metabolism and the possibilities and limitations of microdialysis during routine neurosurgical and general intensive care. Our knowledge of cerebral energy metabolism is to a large extent based on animal experiments performed more than 40 years ago. However, the different biochemical information obtained from various techniques should be recognized. The basic animal studies analyzed brain tissue homogenates while the microdialysis technique reflects the variables in a narrow zone of interstitial fluid surrounding the probe. Besides the difference of the volume investigated, the levels of the biochemical variables differ in different compartments. During bedside microdialysis cerebral energy metabolism is primarily reflected in measured levels of glucose, lactate and pyruvate and the lactate to pyruvate (LP) ratio. The LP ratio reflects cytoplasmatic redox-state which increases instantaneously during insufficient aerobic energy metabolism. Cerebral ischemia is characterized by a marked increase in intracerebral LP ratio at simultaneous decreases in intracerebral levels of pyruvate and glucose. Mitochondrial dysfunction is characterized by a moderate increase in LP ratio at a very marked increase in cerebral lactate and normal or elevated levels of pyruvate and glucose. The patterns are of importance in particular for interpretations in transient cerebral ischemia. A new technique for evaluating global cerebral energy metabolism by microdialysis of the draining cerebral venous blood is discussed. In experimental studies it has been shown that pronounced global cerebral ischemia is reflected in venous cerebral blood. Jugular bulb microdialysis has been investigated in patients suffering from subarachnoid hemorrhage, during cardiopulmonary bypass and resuscitation after out of hospital cardiac arrest. Preliminary results indicate that the new technique may give valuable information of cerebral energy metabolism in clinical conditions when insertion of an intracerebral catheter is contraindicated.
Introduction
Our knowledge regarding cerebral energy metabolism during physiological and pathological conditions is to a large extent based on animal experiments performed more than 40 years ago. Many of these studies were accomplished in a laboratory lead by professor Bo K Siesjö at Lund University Hospital, Sweden, and many important principles were summarized in a textbook and in neurosurgical journals (–). Since then, introduction of new analytical techniques has increased our knowledge considerably (, ) but the basic biochemical patterns established in the original studies are still relevant for intensive care. For many years it has been impossible to monitor cerebral energy metabolism bedside during clinical conditions. However, the development of microdialysis opened up this possibility.
The microdialysis technique was initially developed for monitoring neurotransmitters in the animal brain (, ). In the late 1980s monitoring of the human brain was explored in occasional patients (–). In 1995, CMA Microdialysis (Stockholm, Sweden; present manufacturer M Dialysis, Stockholm, Sweden) introduced a sterile microdialysis catheter, a simple microdialysis pump and an analyzer for bedside enzymatic measurements of variables related to cerebral energy metabolism (glucose, pyruvate, lactate) as well as glutamate and glycerol.
Microdialysis is an open technique that allows analysis of an innumerable number of variables. Under clinical conditions it has been used for studying cytokines and protein biomarkers, performing multiplex proteomic and metabolomic analyses (–) as well as for pharmacokinetic studies and evaluation of blood-brain barrier function (–). This review will focus on the possibilities and limitations of the microdialysis technique when used in critical care for analysis and interpretation cerebral energy metabolism ().
The microdialysis technique
The basic principles of microdialysis are well-known. In 1991 Urban Ungerstedt summarized the principles and applications when the technique is used for studies in animals and man (). We will discuss some aspects of particular importance when cerebral microdialysis is used as a routine technique in neurosurgical as well as in general intensive care utilizing the recently developed technique of performing microdialysis of the draining cerebral blood in the internal jugular vein.
In clinical microdialysis the technique is standardized to permit comparison of data from different centers. During routine microdialysis in neurocritical care a microdialysis catheter with a membrane length of 10 mm and a cut off level of 20 kDa is utilized and perfused at a rate of 0.3 μl/min. The perfusates are collected in microvials and bedside biochemical analysis is usually performed every 60 min. If more frequent sampling is desired, perfusion rate is often increased to 2.0 μl/min.
Due to incomplete recovery, the data obtained for the variables (e.g., glucose, pyruvate, lactate, glutamate, glycerol) does not show their true interstitial levels. During intracerebral microdialysis the relative recovery for these variables has been shown to be approximately 70% at a perfusion rate of 0.3 μl/min and 20–30% at 2.0 μl/min (). For scientific purposes and analyses of large molecules microdialysis membranes with a higher cut off (100 kDa) have been utilized. It has been shown that the dialysate obtained with these catheters may be used for measurements of routine biochemical variables as well (, ).
The time-delay inherent in the microdialysis technique should be noted: the microvial contains the perfusion fluid collected since the previous analysis—usually performed 60 min earlier. However, due to the design of the microvial used in clinical microdialysis the perfusate analyzed usually represents the biochemical composition of the interstitial fluid collected during the last 10 min period. If frequent samples are analyzed another time-delay should be recognized: the delay for the perfusion fluid to pass from the dialysis membrane to the collecting microvial. This problem should be considered also when perfusion rate is relatively high (e g., 2.0 μl/min) ().
The microdialysis catheter collects interstitial fluid from a very narrow zone surrounding the probe and the biochemical patterns obtained are very different if the microdialysis catheter is positioned in the penumbra zone surrounding a focal lesion, in the hemisphere distant from the lesion or in the contralateral hemisphere (). During neurocritical conditions, the perturbation of cerebral energy metabolism is initially often local. Accordingly, an early warning of impending biochemical deterioration is obtained provided the catheter is positioned correctly (Figure 1) (–). Thus, based on bedside biochemical information active interventions may be initiated to limit or prevent tissue damage (). Inversely, an irrelevant alarming biochemical pattern may be obtained if a very local, clinically non-significant lesion or hematoma has developed at the tip of the microdialysis probe. This problems is generally solved by relating the biochemical pattern to the position of the catheter defined from repeat CT-scanning.
Figure 1
In many severe clinical conditions, it would be valuable to compare the very local biochemical data obtained from intracerebral microdialysis to information reflecting “global” cerebral energy metabolic state. Hence, it is of interest to explore whether microdialysate obtained from a catheter positioned in the draining cerebral venous blood might be used for this purpose. In particular, such a technique could be of importance in patients with a global perturbation of cerebral energy metabolism in conditions when insertion of an intracerebral catheter would be difficult or impossible. In these patients it might be possible to position the microdialysis catheter in the bulb of the internal jugular vein. Such clinical studies were preceded by animal experiments to evaluate whether microdialysis of the draining venous blood reflected intracerebral energy metabolism in a meaningful way. However, cerebral venous drainage is very different in different species. In primates, like in man, cerebral blood is mainly drained via the internal jugular vein but in swine the main cerebral venous outflow is through the paraspinal venous network (
Variables reflecting cerebral energy metabolism
As discussed previously, cerebral energy metabolism has been explored in detail during various patho-physiological conditions in experimental studies (
Lactate and pyruvate are water soluble. Due to monocarboxylate transporters (MCTs) they equilibrate rapidly across cellular membranes. MCTs are proton linked membrane carriers present in all tissues and involved in the transport of various monocarboxylates such as lactate, pyruvate and ketone bodies (
Figure 2 gives a simplified illustration of the biochemical variables measured during routine intracerebral microdialysis as well as their reference values in normal human brain and cerebral venous blood measured at the level of the jugular bulb (
Figure 2

Schematic diagram of cerebral intermediary metabolism, with a focus on the glycolytic chain (glucose, pyruvate, lactate) and its relation to glycerol and glycerophospholipids and to the citric acid cycle (Krebs cycle). F-1,6-DP, fructose-1,6-diposphate; DHAP, dihydroxyacetone-phosphate; GA-3P, glyceraldehyde-3-phosphate; G-3-P, glycerol-3-phosphate; FFA, free fatty acids; α-KG, α-ketoglutarate. Underlined metabolites are measured bedside with enzymatic techniques. References levels of the various metabolites for normal human brain obtained from (
Brain tissue may use various substrates for energy metabolism but under normal conditions glucose constitutes the sole substrate of importance (
The lactate/pyruvate (LP) ratio reflects cytoplasmatic redox-state, which can be expressed in terms of the lactate dehydrogenase equilibrium:
The LP ratio gives information regarding the efficacy of cerebral oxidative energy metabolism. The ratio increases during deficient oxygen delivery (ischemia, hypoxia) and mitochondrial dysfunction (
The physiological and biochemical changes during a gradual decrease in cerebral blood flow (CBF) are of particular importance during critical care. At a normal hemoglobin concentration of 150 g/L and 95% saturation, arterial blood contains about 9 μmol of oxygen per mL and arterio-venous oxygen difference is about 3 μmol/mL. Thus, if CBF is reduced to about 1/3 theoretically all oxygen will be extracted. For glucose the following approximate levels have been described: arterial concentration 5.1 μmol/mL; venous concentration 4.6 μmol/mL; arterio-venous glucose difference 0.5 μmol/mL (
Consequently, during a reduction of CBF glucose will not be the limiting factor for maintenance of aerobic energy metabolism and insufficient glucose supply will not cause increase of the LP ratio. It has recently been suggested that the injured brain would benefit from exogenous lactate supplementation (
Biochemical patterns during increased energy metabolism
Hypermetabolism and hyperglycolysis are defined as a significant increase in cerebral metabolic rate above normal causing an increase in cerebral glycolytic rate. Cerebral hypermetabolism may occur during physiological as well as pathological conditions. The steady state levels of the chemical variables related to energy metabolism do not directly reveal metabolic rate but it is important to define the biochemical patterns expected in various hypermetabolic conditions.
Hypermetabolism studied in brain tissue homogenates
Cerebral hypermetabolism has been extensively studied in the rat. During immobilization stress CBF and cerebral metabolic rate for oxygen (CMRO2) increased by about 40 % after 5 min (
In rat experiments the changes in cerebral energy metabolism during sustained epileptic seizures have been studied after administration of i.v. bicucullin and i.p. homocysteine. Seizures induced by bicuculline were accompanied by a 2- to 3-fold increase in cerebral metabolic rate, very marked increases in intracerebral levels of lactate and LP ratio, a moderate increase in pyruvate and a moderate decrease in glucose (
These experimental models show that during moderate cerebral hypermetabolism (immobilization stress) LP ratio is essentially unaffected and cerebral levels of lactate and pyruvate do not change. More pronounced hypermetabolism (homocysteine induced, no seizures) is associated with a moderate increase in LP ratio and modest increases in lactate and pyruvate. During very pronounced hypermetabolism (induced by amphetamine, bicuculline or homocysteine with seizure activity) LP ratio and lactate increases to very high levels while a moderate increase in pyruvate is observed. A moderate decrease in intracerebral glucose occurs after prolonged bicuculline induced seizures. These patterns obtained during experimental studies may be used to interpret clinical situations of suspected hypermetabolism/hyperglycolysis.
Hypermetabolism/hyperglycolysis and clinical intracerebral microdialysis
The biochemical pattern of hyperglycolysis in normal human cerebral cortex has been described during termination of general anesthesia and extubation (
There is limited information regarding cerebral energy metabolism during epileptic seizures in patients evaluated by microdialysis. In a study in patients with traumatic brain lesions Vespa et al. (
To summarize, the experimental studies and the clinical experiences indicate that during moderate cerebral hypermetabolism (arousal, extubation) is associated with an insignificant increase in LP ratio and modest, almost parallel increases in lactate and pyruvate During very pronounced hypermetabolism (epileptic seizures) LP ratio and lactate increases to very high levels accompanied by a moderate increase in pyruvate. After prolonged experimentally induced seizures a moderate decrease in intracerebral glucose occurs. A decrease in glucose has been described during prolonged seizures in patients. The time course of the changes in lactate, pyruvate and LP ratio as well as the simultaneous expected changes in CBF/PbtO2 are schematically illustrated in Figures 3C,D.
Figure 3

Schematic illustration of the simultaneous changes in cerebral blood flow (CBF), brain tissue oxygen tension (PbtO2) and the intracerebral levels of lactate (La), pyruvate (Py) and lactate/pyruvate ratio (LPR) in cerebral ischemia (A), mitochondrial dysfunction (B), arousal (C) and epileptic seizures (D).
Ischemia, mitochondrial dysfunction and hypoxia
The concept of ischemia originates from the Greek words ischein (to restrain) and haima (blood) and is commonly defined as insufficient organ perfusion irrespective of the cause. Under experimental and clinical conditions ischemia will cause different biochemical consequences depending on the degree of CBF restriction. The changes after a momentary, complete interruption of CBF has been studied extensively in animal experiments. In this situation a severe perturbation of energy metabolism is measured within seconds as a marked increase in LP ratio. After a few min glucose and pyruvate are completely depleted and lactate has increased to a maximum level (approximately 12 mmol/L) (
As the LP ratio reflects cytoplasmatic redox-state, an increased ratio does not necessarily indicate cerebral ischemia. Accordingly, in patients treated for severe traumatic brain lesions it has repeatedly been described that increased LP ratio was not explained by a decrease in CBF (
The biochemical pattern of mitochondrial dysfunction obtained utilizing microdialysis has been described after intracerebral infusion of cyanide in the pig (
It should be underlined that the pattern of LP ratio, lactate and pyruvate described for mitochondrial dysfunction (Figure 3B) is not unique for this condition. Figure 4 gives a schematic illustration of the metabolic pattern during normal conditions (A), ischemia (B), mitochondrial dysfunction (C) and hypoxic hypoxia (D). As illustrated in Figure 4D a metabolic pattern similar to mitochondrial dysfunction would be obtained during a selective decrease in arterial oxygen supply (hypoxic hypoxia) (
Figure 4

Schematic illustration of biochemical patterns obtained utilizing intracerebral microdialysis under normal conditions (A), during cerebral ischemia (B), mitochondrial dysfunction (C), and hypoxic hypoxia (D). Mitochondrial dysfunction may be caused by lesions at various steps in the citric acid cycle as indicated by the red bars in (C). The font size reflects the level of the various variables in three conditions compared to their normal reference concentrations.
Cerebral energy metabolism in transient ischemia
Transient cerebral ischemia is common in critical care. The episodes may occur as a single, focal (e.g., cerebral embolism), or global (e.g., hemorrhagic shock, cardiac arrest) event or repeatedly in various severe conditions during neurocritical care. Therefore, to interpret biochemical data obtained during cerebral microdialysis correctly, it is necessary to consider the corresponding data obtained under controlled experimental conditions.
Transient ischemia studied in brain tissue homogenates
The biochemical changes occurring after transient cerebral ischemia have been extensively investigated utilizing brain tissue homogenates in animal experiments (
Under identical experimental conditions, cortical mitochondria were isolated and studied in vitro. After 30 min of ischemia there was a decrease in respiratory control ratio (RCR), in state 3 respiratory activity and maximal phosphorylation rate. However, after recirculation the mitochondria showed extensive functional recovery with normalization of RCR, as well as of state 3 and maximal phosphorylation rates (
A second experimental model was developed to imitate the clinical conditions during transient cerebral ischemia in patients. In this model cortical blood flow was not completely interrupted but reduced to about 5 % of control (
Deficient recirculation has been suggested as a factor limiting restitution following transient cerebral ischemia. Insufficient microcirculation may be caused by a combination of pathophysiological mechanisms such as swelling of endothelial and perivascular cells, intravascular aggregation of blood corpuscles, and increased blood viscosity (
To sum up, animal experiments have documented that mitochondrial function and cerebral aerobic energy metabolism may recover to a large extent after prolonged complete ischemia (30 min) provided adequate recirculation is accomplished. The observation is of importance for restitution e.g., after cardiac arrest and resuscitation. This aspect is discussed in section 8.3. (Microdialysis during resuscitation after out of hospital cardiac arrest).
Intracerebral microdialysis in transient experimental ischemia
For the interpretation of clinical microdialysis data, it is necessary to compare the results obtained from studies utilizing brain homogenates with those observed during transient experimental ischemia and intracerebral microdialysis. For this purpose, transient brain ischemia was induced in fetal lambs in utero by occlusion of the umbilical cord followed by resuscitation after cardiac arrest (
Figure 5

(A): Changes in fetal intracerebral levels of glucose, pyruvate and lactate during cardiac arrest due to umbilical cord occlusion and after resuscitation. Umbilical occlusion and start of resuscitation are indicated in the figure. (B): Changes in intracerebral levels of lactate/pyruvate (LP) ratio, glutamate, and glycerol after umbilical cord occlusion and after resuscitation. Data (Mean levels) from (
These microdialysis data in these experimental studies correspond to those obtained from analyses of brain homogenates and are of fundamental importance for the interpretation of the changes observed during clinical microdialysis. Accordingly, the LP ratio would be expected to increase immediately when delivery of oxygen is insufficient and rapidly return to nearly normal levels upon sufficient re-oxygenation (
Intracerebral microdialysis in transient clinical ischemia
In transient clinical ischemia it is important to interpret the perturbation of cerebral energy metabolism remaining after recirculation correctly: are the observed changes due to continuing ischemia or caused by disturbed aerobic energy metabolism (mitochondrial dysfunction)? We have previously discussed the possibility to separate ischemia from mitochondrial dysfunction from the pattern of the LP ratio in relation to the levels of lactate and pyruvate. These observations were obtained under experimental conditions and may be compared with clinical experiences in patients after recirculation of middle cerebral artery (MCA) infarcts, subarachnoid hemorrhage (SAH), bacterial meningitis and in patients treated for severe brain trauma.
The biochemical patterns observed following severe cerebral ischemia and recirculation is illustrated by the observations after reperfusion in large MCA infarcts. A consecutive series of 44 patients with MCA infarcts and malignant brain swelling were treated with hemicraniectomy. Microdialysis catheters were inserted into the infarcted and the contralateral hemispheres (
Figure 6

Regional cerebral blood flow (CBF) after hemicraniectomy in a patient with malignant brain edema after middle cerebral artery (MCA) infarct (A) and corresponding acute CT scan (B) and CT scan after 6 months (C). (A,B) Shows the position of one intracerebral microdialysis catheter (a) in the infarcted hemisphere. (C) Shows the CT scan 6 months later after replacement of the skull bone. Data from (
Figure 7

(A): Middle cerebral artery (MCA) blood-flow velocities in the infarcted (worse) and non-infarcted (better) hemisphere and cerebral interstitial glucose concentration in infarcted (worse) and non-infarcted (better) hemisphere following hemicraniectomy. (B): Cerebral interstitial levels of lactate/pyruvate (LP) ratio and pyruvate in the infarcted (worse) and non-infarcted hemisphere (better) after hemicraniectomy. The normal ranges for intracerebral glucose and pyruvate (Mean ± 2 S.D.) (
As previously mentioned, a discrepancy between CBF and cerebral energy metabolism was described in patients treated for severe brain trauma (
Figure 8

Total mortality and mortality in four diagnostic groups of severe traumatic brain lesions in 213 patients: Extradural hematoma (EDH); Acute subdural hematoma (SDH); Focal cerebral hemorrhagic contusion (CHC); No Mass denotes patients not treated with surgical evacuation. Mortality is also shown separately for the biochemical subgroups defined as Ischemia (Isch), Mitochondrial Dysfunction (Mit Dysf) and normal aerobic metabolism (LP-ratio ≤ 30) within each diagnostic group. Data from (
In summary, transient cerebral ischemia is a common clinical problem and bedside interpretation of the metabolic patterns obtained may be used to direct therapy. The interpretation should be based on knowledge of the vast amount of experimental data from whole brain analyses and their correlates obtained utilizing microdialysis. During the interpretation the biochemical patterns observed in various pathophysiological conditions must be considered: e.g., ischemia, mitochondrial dysfunction, hypoxic hypoxia, arousal, non-convulsive epileptic activity and epileptic seizures.
Microdialysis of cerebral venous blood—experimental
An experimental model of global cerebral ischemia during hemorrhagic shock in the pig was used to explore whether cerebral energy state might be evaluated from microdialysis of the draining cerebral venous blood (
Figure 9

Mean arterial blood pressure (MAP) and intracerebral levels of glucose and lactate/pyruvate (LP) ratio during 240 min before, during and after a 90 min period (A) and a 60 min period (B) of hemorrhagic shock. In both panels MAP decreased to 40 mmHg. Panel A illustrates the biochemical pattern during severe cerebral ischemia. Panel B illustrates a pattern when intracerebral glucose an LP ratio are relatively unaffected during a similar but shorter decrease in MAP. Data from (
Figure 10

(A): Brain tissue oxygen tension (PbtO2), and lactate/pyruvate (LP) ratio obtained in brain tissue (intracerebral), superior sagittal sinus (sinus), and femoral artery (artery) during severe, irreversible ischemia after induced hemorrhagic shock. (B): Brain tissue oxygen tension (PbtO2), and lactate/pyruvate (LP) ratio obtained in brain tissue (intracerebral) and superior sagittal sinus (sinus) during reversible hemorrhagic shock. Data from (
During severe global brain ischemia microdialysis of the venous drainage gave qualitative information of cerebral energy metabolism that could be separated from the perturbation of energy metabolism in the rest of the body. In accordance with the biochemical pattern in ischemia (Figures 3A, 5B) pyruvate concentration decreased in the intracerebral compartment as well as in the sagittal sinus.
In the following series with a shorter period of hemorrhagic shock, the animals initially tolerated a decrease of MAP to 40 mmHg (Figure 9B) (
In summary, these experimental studies demonstrated that during severe, global brain ischemia semiquantitative information of cerebral energy state could be obtained from microdialysis of the draining cerebral venous blood. In particular, the technique might be of interest in severe, widely spread cerebral ischemia when it is difficult or impossible to insert an intracerebral microdialysis catheter under clinical conditions (e.g., during resuscitation after cardiac arrest).
Microdialysis of cerebral venous blood—clinical
The biochemical information obtained from microdialysis of the draining cerebral blood has been evaluated in three clinical situations: during neurocritical care in patients with SAH, during cardiopulmonary bypass (CPB) in open heart surgery, and during intensive care in patients resuscitated after out of hospital cardiac arrest (OHCA). In all three groups of patients, the intravenous microdialysis catheter was placed in a retrograde direction in the jugular bulb. To prevent clot formation around the microdialysis membranes dalteparin sodium (25 IU/mL) was added to the perfusion fluid of all intravenous and intraarterial catheters in accordance with the recommendations from the manufacturer (M Dialysis, Stockholm, Sweden).
Microdialysis of cerebral venous blood in subarachnoid hemorrhage
This observational study aimed to explore the feasibility of jugular bulb microdialysis (JBMD) in SAH and describe the output characteristics in relation to conventional multimodal monitoring. In particular, it would be of interest to clarify whether episodes of severe cerebral ischemia revealed by intracerebral microdialysis was reflected by JBMD.
Twelve patients treated for aneurysmal SAH were included in the study and monitored for a mean period of 4.2 ± 2.6 days (
The patients were monitored using a non-dominant frontal cerebral microdialysis catheter (70 MD Bolt Catheter, M Dialysis AB, Stockholm) with an ICP and brain oxygen tension (PbtO2) probe in a double lumen bolt (PTO2L, Raumedic®, Helmbrechts). The JBMD catheter (67 IV MD Catheter, M Dialysis AB, Stockholm) was inserted 5 cm above the clavicular bone through a 16 G i.v. cannula. Correct placement of cerebral and jugular bulb catheters (gold tip) was confirmed through regular control computed tomography (CT) imaging.
The study concluded that continuous microdialysis monitoring of the cerebral drainage in the jugular bulb was feasible and safe in patients treated for SAH. With the exception of glucose, there were no significant correlations between intracerebral microdialysis and JBMD at cohort level. The limited number of patients included in this feasibility study precluded a definite answer to the question whether severe cerebral ischemia would be reflected in JBMD. Only two patients (pat. 3 and pat. 9) exhibited an intracerebral biochemical pattern of ischemia.
In pat. 9 intracerebral microdialysis (LP ratio 554, pyruvate 6 μmol/l, glucose 0.3 mmol/l, glutamate 424 μmol/L) was not reflected in JBMD. However, the pattern of metabolites in JBMD documented that the catheter was outside the blood vessel (glutamate 18 μmol/L) and the catheter could not be visualized on CT-scanning.
In pat. 3 intracerebral data indicated severe ischemia (LP ratio 140, pyruvate 40 μmol/L, glucose 0.02 mmol/L, glutamate 109 μmol/L) but all variables were within normal limits in JBMD. In this patient CT showed a minimal hematoma without clinical significance surrounding the intracerebral catheter and the 6-months follow up was favorable.
The latter patient demonstrated that a pathological biochemical pattern obtained during intracerebral microdialysis may be due to a very local lesion without clinical significance. As in most neurosurgical conditions perturbation of energy metabolism is initially local, an early warning of deterioration will be obtained provided the microdialysis catheter is positioned in the penumbra of the focal lesion (Figure 1) (
Another microdialysis technique for evaluation of global cerebral energy metabolism during neurocritical care has been tested (
Microdialysis during cardiopulmonary bypass
Despite considerable progress in surgical CPB and anesthetic techniques brain damage remains an important complication of cardiac surgery (
The LP ratio monitored simultaneously from jugular bulb and intraarterial microdialysis are illustrated in Figure 11. During CPB the peak LP ratio was significantly higher in JBMD documenting that the LP ratio obtained in the jugular bulb was a reflection of cerebral energy metabolism. The increase in intravenous LP ratio above normal level (
Figure 11

Acute effects of cardiopulmonary bypass (CPB) on jugular bulb lactate/pyruvate (LP) ratio and peripheral artery LP ratio. *Significant difference from baseline. **Significant difference between corresponding datapoints by one-way analysis of variance and corrected for multiple comparisons using the Bonferroni test (α = 0.006). Values are median and error with inter quartile range (n = 10). Figure by permission from (
The LP ratios obtained from JBMD in the two MAP groups are shown in Figure 12 (upper panel). The difference in MAP between the two groups was significant (Figure 12, lower panel). After initiating CPB, the mean LP ratio increased significantly by 160% (low MAP) and 130% (high MAP). In both groups, the mean peak LP ratio also increased significantly. However, although low-MAP patients had a tendency to have higher LP ratios (Figure 12, upper panel) the difference between groups was not statistically significant. In both groups, LP ratio returned to baseline after CPB. In spite of the obvious increase in LP ratio during CPB no cerebral desaturations (decrease in rSO2 < 20% from baseline) were observed by NIRS in either group.
Figure 12

Acute effects of cardiopulmonary bypass (CPB) and two levels of mean arterial blood pressure (MAP) on lactate/pyruvate (LP) ratio obtained from a microdialysis catheter placed in the jugular bulb (upper panel) and the simultaneous MAP levels (lower panel). Data are shown as median (IQR). The interrupted line (upper panel) indicates reference level (Mean) for LP ratio in human jugular venous blood (43). *Significant difference from baseline. **Significant difference between corresponding datapoints by one-way analysis of variance and corrected for multiple comparisons using the Bonferroni test (α = 0.006). Values are median and error with inter quartile range (n = 10). Figures by permission from (
In summary, the study documented that it is feasible to place a microdialysis catheter in the jugular bulb during CBP and open-heart surgery. The LP ratio of cerebral venous blood increased significantly during CPB, indicating compromised cerebral oxidative metabolism, and was correlated to the decrease in MAP. In this limited number of patients, there was no significant difference between low-and high-MAP groups regarding venous outflow LP ratio during CPB. Low MAP patients tended to have higher LP ratios but conventional rSO2 monitoring utilizing NIRS did not show a corresponding decrease in cerebral oxygenation. As some patients exhibited decreased cognitive functions after CPB, the study indicated that an increase in jugular venous LP ratio might be a sensitive indicator of impending cerebral damage.
Microdialysis during resuscitation after out of hospital cardiac arrest
Survival rates around 50% are reported in comatose patients resuscitated after out-of-hospital cardiac arrest OHCA (
A feasibility study was designed to investigate if bedside JBMD reflected secondary deterioration of cerebral energy metabolism after OHCA and whether it might be implemented as a clinical tool for early evaluation of prognosis and individualization of treatment (
Eighteen unconscious patients with sustained return of spontaneous circulation (ROSC) after OHCA were included in the study (
JBMD was initiated after ICU admission (approximately 300 min after ROSC) and continued for 96 h or until arousal. Intravenous MD catheters (67 IV, M Dialysis AB, Stockholm, Sweden) were inserted in one jugular vein and one peripheral artery and perfused and analyzed as previously described (section 8.1). The definition of normal levels of the studied variables in human jugular vein blood was based on JBM reference values obtained in anesthetized patients undergoing elective cardiac bypass surgery (
The changes over time in arterial and jugular microdialysis for patients in the poor outcome (CPC 3–5) group ratio is compared in Figure 13 (left panels) regarding lactate and pyruvate as well as the calculated LP ratio. The difference between time-averaged means of LP ratio, lactate and pyruvate were significant (p < 0.02) during the periods indicated in the figure. JBMD also showed significantly elevated levels of glycerol compared to systemic MD in the first 50 h after ROSC. Further, in the late post-resuscitation period glutamate concentration was significantly higher than the arterial level. In patients with favorable outcome (CPC 1–2). The differences between time-averaged mean JBMD variables and corresponding systemic values were, except for glycerol, statistically non-significant.
Figure 13

Left panels: microdialysis variables (LP ratio, lactate, pyruvate) of the jugular venous and arterial blood during post-resuscitation care after out of hospital cardiac arrest in patients with unfavorable outcome. Right panels: jugular bulb microdialysis variables (LP ratio, lactate, pyruvate) during post-resuscitation care in patients with unfavorable outcome (CPC 3–5) compared with patients with favorable outcome (CPC 1–2). The period of targeted temperature management (TTM) is indicated in the figures. The difference between time-averaged means (in intervals of 12 h) of LP ratio, lactate, pyruvate, glycerol and glutamate of the jugular venous and the arterial blood was significant during post-resuscitation care (*p < 0.02) when using mixed effects models. Data are shown as median (IQR). Shaded areas represent normal reference levels for the variables during jugular bulb microdialysis (
The LP ratio in jugular blood remained elevated (> 16) during the first 20 h in both outcome groups as shown in Figure 13 (right panels). After 20 h, an almost complete normalization of the LP ratio was observed. However, the cerebral level of lactate remained high in the CPC 3–5 group (mean level > 2.7 mM), and was paralleled by a marked increase in pyruvate. Based on the biochemical definitions presented previously six patients with unfavorable outcome exhibited ongoing secondary ischemia during altogether 45 h (20%) of the first 24 h of MD monitoring. In the favorable group, three patients displayed a pattern of ischemia during altogether 13 h (13%). Biochemical signs interpreted as mitochondrial dysfunction was noticed in 46% in patients with unfavorable outcome (n = 13) and 38% of the time in patients with favorable outcome (n = 5).
As discussed previously, a sudden interruption of CBF is instantaneously reflected in a shift in cytoplasmic redox state and a marked increase in cerebral LP ratio (Figure 5B) (
In the present clinical study, it was for practical reasons not possible to start JBMD and obtain biochemical data until approximately 4–7 h after ROSC. In spite of this delay remaining cerebral ischemia was diagnosed in altogether nine patients during the initial 24 h of MD. The observation contrasts to experiences in experimental studies presented above. In these studies, biochemical signs of remaining ischemia were not observed 90 min after recirculation (
Cerebral reperfusion after OHCA is complex and there is a lack of data regarding the 1 h after ROSC (
The data obtained in this first explorative, feasibility study have recently been extended in a large randomized study and the intentions of the study have been published (
Concluding remarks
The value of routine cerebral microdialysis is dependent on valid clinical interpretation of the biochemical data displayed bedside. When the information from microdialysis is added to other chemical and physiological data as well as indexes calculated during neurocritical care, very large amounts of data are collected from each patient. It may then seem tempting to process this mass of data with sophisticated statistical methods to reveal correlations between variables with the intention of facilitating biochemical interpretation and support therapeutic choices. As shown in a very large, recent study the information obtained from this approach give little useful information for bedside interpretation (
In this review, we have presented our experiences regarding interpretation of the patterns of variables related to cerebral energy metabolism during routine cerebral microdialysis. Bedside biochemical interpretations should be based on experiences obtained from systematic studies. Interpretations based on occasional clinical observations in various pathological conditions should be questioned if they are not supported by known biochemical patterns documented in systematic experimental and clinical studies.
The recommendations presented above may be summarized in 5 items:
Bedside interpretation of biochemical data should be based on principles of cerebral energy metabolism established in animal experiments or controlled, systematic clinical studies. Most of the basic biochemical information has been obtained from analyses of brain homogenates and the difference between these data and later data obtained from microdialysis of cerebral interstitial fluid should be noted.
The principles and limitations of the microdialysis technique should be taken into account as well as the analytical precision of the techniques used for routine analyzes.
As cerebral energy state depends on aerobic degradation of glucose, bedside analysis and display of the interstitial levels of glucose, pyruvate and lactate give a valid evaluation of cerebral energy metabolism. The calculated, interstitial LP ratio reflects cytoplasmatic redox state. Under clinical conditions, an increase in LP ratio is primarily observed in ischemia, hypoxic hypoxia and mitochondrial dysfunction. The levels obtained for the biochemical variables should be compared to the levels (Mean ± SD) published for normal human brain when utilizing identical microdialysis and analytical techniques. For clinical interpretation it is useful to regard a high LP ratio at a simultaneously very low pyruvate level as cerebral ischemia, and a high LP ratio at a normal or high pyruvate level as indication of cerebral mitochondrial dysfunction.
Intracerebral microdialysis reflects biochemical variables in a very narrow zone of the surrounding interstitial fluid. In neurocritical care cerebral lesions are often initially local or regional and the positioning of the microdialysis catheter is therefore crucial. If the catheter is placed in a penumbra zone surrounding a focal lesion an early warning of impending deterioration may direct therapy before signs of deterioration is observed by other techniques. The positioning of the catheter should always be confirmed by CT-scanning. Insertion of more than one intracerebral microdialysis catheter will increase the clinically useful information.
Microdialysis of cerebral venous blood in the jugular bulb (JBMD) has shown promise to give information of cerebral energy metabolism under certain conditions. The technique appears to be of clinical value in patients with pronounced global perturbation of cerebral energy metabolism especially when it is difficult or impossible to insert intracerebral microdialysis catheters. In patients resuscitated after cardiac arrest the technique have in recent studies indicated that a poor clinical outcome is related to insufficient cerebral circulation several hours after return of spontaneous circulation.
Finally, for routine clinical use the conventional technique of collecting the microdialysate into microvials at regular time intervals for transport to a bedside analyzer is labor intensive and time consuming. The clinical use of microdialysis would probably increase if the dialysate was analyzed on-line by biosensors and the results immediately displayed on a bedside monitor.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
The microdialysis technique was invented and developed by UU. The biochemical background was mainly based on previous experimental studies by C-HN. The clinical studies were mainly conducted at Odense University Hospital and were mainly designed, performed and interpreted by TN, AF, SM, PT, and C-HN. The experimental studies on microdialysis of the draining cerebral blood flow were mainly designed, performed and interpreted by RJ, TN, and C-HN at Odense University Hospital, Denmark. All authors have contributed equally to the design, composition, and writing of this comprehensive review.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
SiesjöBK. Brain Energy Metabolism. New York, NY: John Wiley (1978).
2.
SiesjöBK. Cerebral circulation and metabolism. J Neurosurg. (1984) 60:883–908. 10.3171/jns.1984.60.5.0883
3.
SiesjöBK. Pathophysiology and treatment of focal cerebral ischemia. Part I: pathophysiology. J Neurosurg. (1992) 77:169–84. 10.3171/jns.1992.77.2.0169
4.
SiesjöBK. Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J Neurosurg. (1992) 77:337–54. 10.3171/jns.1992.77.3.0337
5.
DienelGA. Brain lactate metabolism: the discoveries and the controversies. J Cereb Blood Flow Metab. (2012) 32:1107–38. 10.1038/jcbfm.2011.175
6.
DienelGARothmanDLNordströmCH. Microdialysate concentration changes do not provide sufficient information to evaluate metabolic effects of lactate supplementation in brain-injured patients. J Cereb Blood Flow Metab. (2016) 36:1844–64. 10.1177/0271678X16666552
7.
UngerstedtUPycockC. Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss. (1974) 30:44–55.
8.
UngerstedtU. Measurement of neurotransmitter release by intracranial dialysis. In: Marsden CA editor Measurement of neurotransmitter release in vivo. Chichester; New York, NY; Brisbane, QLD; Toronto, ON: John Wiley & Son Ltd (1984). p. 81–105.
9.
UngerstedtU. Microdialysis-principles and applications for studies in animals and man. J Intern Med. (1991) 230:365–73. 10.1111/j.1365-2796.1991.tb00459.x
10.
MeyersonBALinderothBKarlssonHUngerstedtU. Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients. Life Sci. (1990) 46:301–8. 10.1016/0024-3205(90)90037-R
11.
HilleredLPerssonLPonténUUngerstedtU. Neurometabolic monitoring of the ischaemic human brain using microdialysis. Acta Neurochir (Wien). (1990) 102:91–7. 10.1007/BF01405420
12.
HutchinsonPJJallohIHelmyACarpenterKLRostamiEBellander BM etal. Consensus statement from the 2014 International Microdialysis Forum. Intensive Care Med. (2015) 41:1517–28. 10.1007/s00134-015-3930-y
13.
HilleredLDahlinAPClausenFChuJBergquistJHjortKet al. Cerebral microdialysis for protein biomarker monitoring in the neurointensive care setting - a technical approach. Front Neurol. (2014) 5:245. 10.3389/fneur.2014.00245
14.
ZeilerFAThelinEPCzosnykaMHutchinsonPJMenonDKHelmyA. Cerebrospinal fluid and microdialysis cytokines in severe traumatic brain injury: a scoping systematic review. Front Neurol. (2017) 8:331. 10.3389/fneur.2017.00331
15.
ErcoleAMagnoniSVeglianteGPastorelliRSurmackiJBohndiek SE etal. Current and emerging technologies for probing molecular signatures of traumatic brain injury. Front Neurol. (2017) 8:450. 10.3389/fneur.2017.00450
16.
ChaurasiaCSMüllerMBashawEDBenfeldtEBolinderJBullock R etal. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. (2007) 24:1014–25. 10.1007/s11095-006-9206-z
17.
EderothPTunbladKBouwRLundbergCJUngerstedtUNordström CH etal. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol. (2004) 57:427–35. 10.1046/j.1365-2125.2003.02032.x
18.
TunbladKEderothPGärdenforsAHammarlund-UdenaesMNordströmCH. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand. (2004) 48:294–301. 10.1111/j.0001-5172.2003.0311.x
19.
BengtssonJEderothPLeyDHanssonSAmer-WåhlinIHellström-Westas L etal. The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. Br J Pharmacol. (2009) 157:1085–96. 10.1111/j.1476-5381.2009.00242.x
20.
ShannonRJCarpenterKLGuilfoyleMRHelmyAHutchinsonPJ. Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications. J Pharmacokinet Pharmacodyn. (2013) 40:343–58. 10.1007/s10928-013-9306-4
21.
NordströmCH. Cerebral microdialysis in TBI-limitations and possibilities. Acta Neurochir (Wien). (2017) 159:2275–7. 10.1007/s00701-017-3339-1
22.
HutchinsonPJO'ConnellMTAl-RawiPGMaskellLBKett-WhiteRGupta AK etal. Clinical cerebral microdialysis: a methodological study. J Neurosurg. (2000) 93:37–43. 10.3171/jns.2000.93.1.0037
23.
HutchinsonPJO'ConnellMTNortjeJSmithPAl-RawiPGGuptaAKet al. Cerebral microdialysis methodology–evaluation of 20 kDa and 100 kDa catheters. Physiol Meas. (2005) 26:423–8. 10.1088/0967-3334/26/4/008
24.
HillmanJMilosPYuZQSjögrenFAndersonCMellergårdP. Intracerebral microdialysis in neurosurgical intensive care patients utilising catheters with different molecular cut-off (20 and 100 kD). Acta Neurochir (Wien). (2006) 148:319–24. 10.1007/s00701-005-0670-8
25.
NordströmCHJakobsenRMølstrømSNielsenTH. Cerebral microdialysis after cardiac arrest - Misinterpretations based on a misconception. Resuscitation. (2021) 169:227–8. 10.1016/j.resuscitation.2021.10.045
26.
EngströmMPolitoAReinstrupPRomnerBRydingEUngerstedtUet al. Intracerebral microdialysis in severe brain trauma: the importance of catheter location. J Neurosurg. (2005) 102:460–9. 10.3171/jns.2005.102.3.0460
27.
StåhlNMellergårdPHallströmAUngerstedtUNordströmCH. Intracerebral microdialysis and bedside biochemical analysis in patients with fatal traumatic brain lesions. Acta Anaesthesiol Scand. (2001) 45:977–85. 10.1034/j.1399-6576.2001.450810.x
28.
StåhlNUngerstedtUNordströmCH. Brain energy metabolism during controlled reduction of cerebral perfusion pressure in severe head injuries. Intensive Care Med. (2001) 27:1215–23. 10.1007/s001340101004
29.
NordströmCHReinstrupPXuWGärdenforsAUngerstedtU. Assessment of the lower limit for cerebral perfusion pressure in severe head injuries by bedside monitoring of regional energy metabolism. Anesthesiology. (2003) 98:809–14. 10.1097/00000542-200304000-00004
30.
StåhlNSchalénWUngerstedtUNordströmCH. Bedside biochemical monitoring of the penumbra zone surrounding an evacuated acute subdural haematoma. Acta Neurol Scand. (2003) 108:211–5. 10.1034/j.1600-0404.2003.00095.x
31.
WinbergJHolmICederbergDRundgrenMKronvallEMarklundN. Cerebral microdialysis-based interventions targeting delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. Neurocrit Care. (2022) 37:255–66. 10.1007/s12028-022-01492-5
32.
LavoiePMetellusPVellyLVidalVRollandPHMekaouche M etal. Functional cerebral venous outflow in swine and baboon: feasibility of an intracranial venous hypertension model. J Invest Surg. (2008) 21:323–9. 10.1080/08941930802438880
33.
HabibCAUtriainenDPeduzzi-NelsonJDaweEMatteiJLatif Z etal. MR imaging of the yucatan 64 pig head and neck vasculature. J Magn Reson Imaging. (2013) 38:641–9. 10.1002/jmri.24003
34.
NedergaardMTakanoTHansenAJ. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci. (2002) 3:748–55. 10.1038/nrn916
35.
PooleRCHalestrapAP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol. (1993) 264:C761–82. 10.1152/ajpcell.1993.264.4.C761
36.
HalestrapAPPriceNT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J. (1999) 343:281–99. 10.1042/bj3430281
37.
PierreKPellerinL. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem. (2005) 94:1–14. 10.1111/j.1471-4159.2005.03168.x
38.
HalestrapAPWilsonMC. The monocarboxylate transporter family–role and regulation. IUBMB Life. (2012) 64:109–19. 10.1002/iub.572
39.
BoumezbeurFPetersenKFClineGWMasonGFBeharKLShulmanGIet al. The contribution of blood lactate to brain energy metabolism in humans measured by dynamic 13C nuclear magnetic resonance spectroscopy. J Neurosci. (2010) 30:13983–91. 10.1523/JNEUROSCI.2040-10.2010
40.
HalestrapAP. The monocarboxylate transporter family–Structure and functional characterization. IUBMB Life. (2012) 64:1–9. 10.1002/iub.573
41.
EnersonBEDrewesLR. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci. (2003) 92:1531–44. 10.1002/jps.10389
42.
ReinstrupPStåhlNMellergårdPUskiTUngerstedtUNordströmCH. Intracerebral microdialysis in clinical practice. Normal values and variations during anaesthesia and neurosurgical operations. Neurosurgery. (2000) 47:701–10. 10.1227/00006123-200009000-00035
43.
MölströmSNielsenTHAndersenCNordströmCHToftP. Bedside monitoring of cerebral energy state during cardiac surgery-a novel approach utilizing intravenous microdialysis. J Cardiothorac Vasc Anesth. (2017) 31:1166–73. 10.1053/j.jvca.2016.11.001
44.
LjunggrenBSchutzHSiesjöBK. Changes in energy state and acid-base parameters of the rat brain during complete compression ischemia. Brain Res. (1974) 73:277–89. 10.1016/0006-8993(74)91049-X
45.
NilssonBNorbergKNordströmCHSiesjöBK. Rate of energy utilization in the cerebral cortex of rats. Acta Physiol Scand. (1975) 93:569–71. 10.1111/j.1748-1716.1975.tb05852.x
46.
NordströmCHSiesjöBK. Influence of phenobarbital on changes in the metabolites of the energy reserve of the cerebral cortex following complete ischemia. Acta Physiol Scand. (1978) 104:271–80. 10.1111/j.1748-1716.1978.tb06279.x
47.
NorbergKSiesjöBK. Cerebral metabolism in hypoxic hypoxia. I Pattern of activation of glycolysis: a re-evaluation. Brain Res. (1975) 86:31–44. 10.1016/0006-8993(75)90635-6
48.
NielsenTHOlsenNVToftPNordströmCH. Cerebral energy metabolism during mitochondrial dysfunction induced by cyanide in piglets. Acta Anaesthesiol Scand. (2013) 57:793–801. 10.1111/aas.12092
49.
LewisLDLjunggrenBNorbergKSiesjöBK. Changes in carbohydrate substrates, amino acids and ammonia in the brain during insulin-induced hypoglycemia. J Neurochem. (1974) 23:659–71. 10.1111/j.1471-4159.1974.tb04389.x
50.
LewisLDLjunggrenBRatchesonRASiesjöBK. Cerebral energy state in insulin-induced hypoglycemia, related to blood glucose and to EEG. J Neurochem. (1974) 23:673–9. 10.1111/j.1471-4159.1974.tb04390.x
51.
AgardhCDKalimoHOlssonYSiesjöBK. Hypoglycemic brain injury. I Metabolic and light microscopic findings in rat cerebral cortex during profound insulin-induced hypoglycemia and in the recovery period following glucose administration. Acta Neuropathol. (1980) 50:31–41. 10.1007/BF00688532
52.
BouzatPSalaNSuysTZerlauthJBMarques-VidalPFeihl F etal. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. (2014) 40:412–21. 10.1007/s00134-013-3203-6
53.
QuintardHPatetCZerlauthJBSuysTBouzatPPellerin L etal. Improvement of neuroenergetics by hypertonic lactate therapy in patients with traumatic brain injury is dependent on baseline cerebral lactate/pyruvate ratio. J Neurotrauma. (2016) 33:681–7. 10.1089/neu.2015.4057
54.
CarlssonCHägerdalMSiesjöBK. Increase in cerebral oxygen uptake and blood flow in immobilization stress. Acta Physiol Scand. (1975) 95:206–8. 10.1111/j.1748-1716.1975.tb10044.x
55.
BerntmanLCarlssonCHägerdalMSiesjöBK. Cerebral metabolic state after discontinuation of nitrous oxide supply in artificially ventilated rats. Acta Physiol Scand. (1976) 98:248–56. 10.1111/j.1748-1716.1976.tb00243.x
56.
BerntmanLCarlssonCHägerdalMSiesjöBK. Circulatory and metabolic effects in the brain induced by amphetamine sulphate. Acta Physiol Scand. (1978) 102:310–23. 10.1111/j.1748-1716.1978.tb06078.x
57.
ChapmanAGMeldrumBSSiesjöBK. Cerebral metabolic changes during prolonged epileptic seizures in rats. J Neurochem. (1977) 28:1025–35. 10.1111/j.1471-4159.1977.tb10665.x
58.
BlennowGFolbergrováJNilssonBSiesjöBK. Effects of bicuculline-induced seizures on cerebral metabolism and circulation of rats rendered hypoglycemic by starvation. Ann Neurol. (1979) 5:139–51. 10.1002/ana.410050207
59.
BlennowGFolbergrovaJNilssonBSiesjöBK. Cerebral metabolic and circulatory changes in the rat during sustained seizures induced by DL-homocysteine. Brain Res. (1979) 179:129–46. 10.1016/0006-8993(79)90497-9
60.
CesariniKGEnbladPRonne-EngströmEMarklundNSalciKNilsson P etal. Early cerebral hyperglycolysis after subarachnoid haemorrhage correlates with favourable outcome. Acta Neurochir (Wien). (2002) 144:1121–31. 10.1007/s00701-002-1011-9
61.
VespaPTubiMClaassenJBuitrago-BlancoMMcArthurDVelazquez AG etal. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol. (2016) 79:579–90. 10.1002/ana.24606
62.
HlatkyRValadkaABGoodmanJCContantCFRobertsonCS. Patterns of energy substrates during ischemia measured in the brain by microdialysis. J Neurotrauma. (2004) 21:894–906. 10.1089/0897715041526195
63.
VespaPBergsneiderMHattoriNWuHMHuangSCNartinNAet al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab. (2005) 25:763–74. 10.1038/sj.jcbfm.9600073
64.
NordströmCHNielsenTHSchalénWReinstrupPUngerstedtU. Biochemical indications of cerebral ischaemia and mitochondrial dysfunction in severe brain trauma analysed with regard to type of lesion. Acta Neurochir (Wien). (2016) 158:1231–40. 10.1007/s00701-016-2835-z
65.
LjunggrenBRatchesonRASiesjöBK. Cerebral metabolic state following complete compression ischemia. Brain Res. (1974) 73:291–307. 10.1016/0006-8993(74)91050-6
66.
FolbergrováJLjunggrenBNorbergKSiesjöBK. Influence of complete ischemia on glycolytic metabolites, citric acid cycle intermediates, and associated amino acids in the rat cerebral cortex. Brain Res. (1974) 80:265–79. 10.1016/0006-8993(74)90690-8
67.
NordströmCHRehncronaSSiesjöBK. Restitution of cerebral energy state, as well as of glycolytic metabolites, citric acid cycle intermediates and associated amino acids after 30 minutes of complete ischemia in rats anaesthetized with nitrous oxide or phenobarbital. J Neurochem. (1978) 30:479–86. 10.1111/j.1471-4159.1978.tb06553.x
68.
RehncronaSMelaLSiesjöBK. Recovery of brain mitochondrial function in the rat after complete and incomplete cerebral ischemia. Stroke. (1979) 10:437–46. 10.1161/01.STR.10.4.437
69.
NordströmCHSiesjöBK. Effects of phenobarbital in cerebral ischemia. Part I: cerebral energy metabolism during pronounced incomplete ischemia. Stroke. (1978) 9:327–35. 10.1161/01.STR.9.4.327
70.
NordströmCHRehncronaSSiesjöBK. Effects of phenobarbital in cerebral ischemia. Part II: restitution of cerebral energy state, as well as of glycolytic metabolites, citric acid cycle intermediates and associated amino acids after pronounced incomplete ischemia. Stroke. (1978) 9:335–43. 10.1161/01.STR.9.4.335
71.
AmesAIIIWrightRLKowadaMThurstonJM. Majno G. Cerebral ischemiaII The no-reflow phenomenon. Am J Pathol. (1968) 52:437–53.
72.
CantuRCAmesAIIIDixonJDigiacintoG. Reversibility of experimental cerebrovascular obstruction induced by complete ischemia. J Neurosurg. (1969) 31:429–31. 10.3171/jns.1969.31.4.0429
73.
ChiangJKowadaMAmesAIIIWrightRLMajnoG. Cerebral ischemia. III Vascular changes. Am J Pathol. (1968) 52:455–76.
74.
FischerEGAmesAIII. Studies on mechanisms of impairment of cerebral circulation following ischemia: effect of hemodilution and perfusion pressure. Stroke. (1972) 3:538–42. 10.1161/01.STR.3.5.538
75.
NordströmCHRehncronaS. Postischemic cerebral blood flow and oxygen utilization rate in rats anesthetized with nitrous oxide or phenobarbital. Acta Physiol Scand. (1977) 101:230–40. 10.1111/j.1748-1716.1977.tb06002.x
76.
RehncronaSRosénISiesjöBK. Brain lactic acidosis and ischemic cell damage: 1. Biochemistry and neurophysiology. J Cereb Blood Flow Metab. (1981) 1:297–311. 10.1038/jcbfm.1981.34
77.
KalimoHRehncronaSSöderfeldtBOlssonYSiesjöBK. Brain lactic acidosis and ischemic cell damage: 2. Histopathology. J Cereb Blood Flow Metab. (1981) 1:313–27. 10.1038/jcbfm.1981.35
78.
RehncronaSKågströmE. Tissue lactic acidosis and ischemic brain damage. Am J Emerg Med. (1983) 1:168–74. 10.1016/0735-6757(83)90085-2
79.
Amer-WåhlinINordABottalicoBHanssonSRLeyDMarsál K etal. Fetal cerebral energy metabolism and electrocardiogram during experimental umbilical cord occlusion and resuscitation. J Matern Fetal Neonatal Med. (2010) 23:158–66. 10.3109/14767050903067360
80.
ForsseANielsenTHNygaardKHNordströmCHGramsbergenJBPoulsenFR. Cyclosporin a ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia. Sci Rep. (2019) 9:3702. 10.1038/s41598-019-40245-x
81.
HavelundJFNygaardKHNielsenTHNordströmCHPoulsenFRFærgeman NJ etal. In vivo microdialysis of endogenous and 13 C-labeled TCA metabolites in rat brain: Reversible and persistent effects of mitochondrial inhibition and transient cerebral ischemia. Metabolites. (2019) 9:204. 10.3390/metabo9100204
82.
NygaardKHHavelundJFNielsenTHNordströmCHFærgemanNJPoulsen FR etal. Ethyl pyruvate increases post-ischemic levels of mitochondrial energy metabolites: a 13 C-labeled cerebral microdialysis study. Metabolites. (2020) 10:287. 10.3390/metabo10070287
83.
EnbladPFrykholmPValtyssonJSilanderHCAnderssonJFasthKJet al. Middle cerebral artery occlusion and reperfusion in primates monitored by microdialysis and sequential positron emission tomography. Stroke. (2001) 32:1574–80. 10.1161/01.STR.32.7.1574
84.
NordmarkJEnbladPRubertssonS. Cerebral energy failure following experimental cardiac arrest hypothermia treatment reduces secondary lactate/pyruvate-ratio increase. Resuscitation. (2009) 80:573–9. 10.1016/j.resuscitation.2009.02.003
85.
SalazarJDColemanRDGriffithSMcNeilJDSteigelmanMYoung H etal. Selective cerebral perfusion: real-time evidence of brain oxygen and energy metabolism preservation. Ann Thorac Surg. (2009) 88:162–9. 10.1016/j.athoracsur.2009.03.084
86.
PutzerGMartiniJSpraiderPHornungRPinggeraDAbram J etal. Effects of different adrenaline doses on cerebral oxygenation and cerebral metabolism during cardiopulmonary resuscitation in pigs. Resuscitation. (2020) 156:223–29. 10.1016/j.resuscitation.2020.06.024
87.
PutzerGMartiniJSpraiderPAbramJHornungRSchmidt C etal. Adrenaline improves regional cerebral blood flow, cerebral oxygenation and cerebral metabolism during CPR in a porcine cardiac arrest model using low-flow extracorporeal support. Resuscitation. (2021) 168:151–59. 10.1016/j.resuscitation.2021.07.036
88.
SkåreCKarlsenHStrand-AmundsenRJEriksenMSkulbergVMSunde K etal. Cerebral perfusion and metabolism with mean arterial pressure 90 vs. 60 mmHg in a porcine post cardiac arrest model with and without targeted temperature management. Resuscitation. (2021) 167:251–60. 10.1016/j.resuscitation.2021.06.011
89.
NielsenTHStåhlNSchalénWReinstrupPToftPNordströmCH. Recirculation usually precedes malignant edema in middle cerebral artery infarcts. Acta Neurol Scand. (2012) 126:404–10. 10.1111/j.1600-0404.2012.01664.x
90.
NielsenTHSchalénWStåhlNToftPReinstrupPNordströmCH. Bedside diagnosis of mitochondrial dysfunction after malignant middle cerebral artery infarction. Neurocrit Care. (2014) 21:35–42. 10.1007/s12028-013-9875-5
91.
JacobsenANielsenTHNilssonOSchalénWNordströmCH. Bedside diagnosis of mitochondrial dysfunction in aneurysmal subarachnoid hemorrhage. Acta Neurol Scand. (2014) 130:156–63. 10.1111/ane.12258
92.
PoulsenFRSchulzMJacobsenAAndersenÅBLarsenLSchalén W etal. Bedside evaluation of cerebral energy metabolism in severe community-acquired bacterial meningitis. Neurocrit Care. (2015) 22:221–8. 10.1007/s12028-014-0057-x
93.
LarsenLNielsenTHNordströmCHAndersenABSchierbeckJSchulzMKet al. Patterns of cerebral tissue oxygen tension and cytoplasmic redox state in bacterial meningitis. Acta Anaesthesiol Scand. (2019) 63:329–36. 10.1111/aas.13278
94.
JakobsenRHalfeld NielsenTGranfeldtAToftPNordströmCH. A technique for continuous bedside monitoring of global cerebral energy state. Intensive Care Med Exp. (2016) 4:3. 10.1186/s40635-016-0077-2
95.
JakobsenRPNielsenTHMølstrømSNordströmCHGranfeldtAToftP. Moderately prolonged permissive hypotension results in reversible metabolic perturbation evaluated by intracerebral microdialysis - an experimental animal study. Intensive Care Med Exp. (2019) 7:67. 10.1186/s40635-019-0282-x
96.
ForsseANielsenTHMølstrømSHjelmborgJNielsenKSNygaard KH etal. A prospective observational feasibility study of jugular bulb microdialysis in subarachnoid hemorrhage. Neurocrit Care. (2020) 33:241–55. 10.1007/s12028-019-00888-0
97.
ThelinEPNelsonDWGhatanPHBellanderBM. Microdialysis monitoring of CSF parameters in severe traumatic brain injury patients: a novel approach. Front Neurol. (2014) 5:159. 10.3389/fneur.2014.00159
98.
AhonenJ. SalmenperaM. Brain injury after adult cardiac surgery. Acta Anaesthesiol. (2004) 48:4–19. 10.1111/j.1399-6576.2004.00275.x
99.
McDonaghDLBergerMMathewJPGraffagninoCMilanoCANewmanMF. Neurological complications of cardiac surgery. Lancet Neurol. (2014) 13:490–502. 10.1016/S1474-4422(14)70004-3
100.
VrankenNPAWeerwindPWSutedjaNAŠeverdijaEEBarenbrugPJCMaessenJG. Cerebral oximetry and autoregulation during cardiopulmonary bypass: a review. J Extra Corpor Technol. (2017) 49:182–91.
101.
MartinellLNielsenNHerlitzJKarlssonTHornJWise MP etal. Early predictors of poor outcome after out-of-hospital cardiac arrest. Crit Care. (2017) 21:96. 10.1186/s13054-017-1677-2
102.
NielsenNWetterslevJCronbergTErlingeDGascheY.HassagerCet al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. (2013) 369:2197–206. 10.1056/NEJMoa1310519
103.
GräsnerJTWnentJHerlitzJPerkinsGDLeferingRTjelmeland I etal. Survival after out-of-hospital cardiac arrest in Europe—Results of the EuReCa TWO study. Resuscitation. (2020) 148:218–26. 10.1016/j.resuscitation.2019.12.042
104.
Sekhon MSAinsliePNGriesdaleDE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: A “two-hit” model. Crit Care. (2017) 21:90. 10.1186/s13054-017-1670-9
105.
SekhonMSGooderhamPMenonDKBrasherPMAFosterDCardim D etal. The burden of brain hypoxia and optimal mean arterial pressure in patients with hypoxic ischemic brain injury after cardiac arrest. Crit Care Med. (2019) 47:960–9. 10.1097/CCM.0000000000003745
106.
Busl KMGreerDM. Hypoxic-ischemic brain injury: pathophysiology, neuropathology and mechanisms. Neuro Rehabilitation. (2010) 26:5–13. 10.3233/NRE-2010-0531
107.
MölströmSNielsenTHNordströmCHForsseAMöllerSVenö S etal. Bedside microdialysis for detection of early brain injury after out-of-hospital cardiac arrest. Sci Rep. (2021) 11:15871. 10.1038/s41598-021-95405-9
108.
KilbaughTJSuttonRMKarlssonMHanssonMJNaimMYMorgan RW etal. Persistently altered brain mitochondrial bioenergetics after apparently successful resuscitation from cardiac arrest. J Am Heart Assoc. (2015) 4:e002232. 10.1161/JAHA.115.002232
109.
XuKPuchowiczMASunXYLaMannaJC. Decreased brainstem function following cardiac arrest and resuscitation in aged rat. Brain Res. (2010) 1328:181–89. 10.1016/j.brainres.2010.02.080
110.
MölströmSNielsenTHNordströmCHHassagerCMøllerJEKjærgaard J etal. Design paper of the “Blood pressure targets in post-resuscitation care and bedside monitoring of cerebral energy state: a randomized clinical trial”. Trials. (2019) 20:344. 10.1186/s13063-019-3397-1
111.
GuilfoyleMRHelmyADonnellyJStovellMGTimofeevIPickard JD etal. Characterising the dynamics of cerebral metabolic dysfunction following traumatic brain injury: a microdialysis study in 619 patients. PLoS ONE. (2021) 16:e0260291. 10.1371/journal.pone.0260291
Summary
Keywords
microdialysis, cerebral energy metabolism, ischemia, mitochondrial dysfunction, lactate, pyruvate, cardiac arrest, resuscitation
Citation
Nordström C-H, Forsse A, Jakobsen RP, Mölström S, Nielsen TH, Toft P and Ungerstedt U (2022) Bedside interpretation of cerebral energy metabolism utilizing microdialysis in neurosurgical and general intensive care. Front. Neurol. 13:968288. doi: 10.3389/fneur.2022.968288
Received
13 June 2022
Accepted
11 July 2022
Published
10 August 2022
Volume
13 - 2022
Edited by
Jefferson W. Chen, University of California, Irvine, United States
Reviewed by
Ibrahim Jalloh, University of Cambridge, United Kingdom; Patrick M. Chen, Harvard Medical School, United States
Updates

Check for updates
Copyright
© 2022 Nordström, Forsse, Jakobsen, Mölström, Nielsen, Toft and Ungerstedt.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Carl-Henrik Nordström carl-henrik.nordstrom@med.lu.se
This article was submitted to Neurocritical and Neurohospitalist Care, a section of the journal Frontiers in Neurology
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.